Mechanism
Tirzepatide is a single 39-amino-acid peptide engineered to activate two incretin receptors at once. That dual action is what separates it mechanistically from the earlier GLP-1-only agonists.
| Mechanism | Detail |
|---|---|
| GLP-1 receptor agonism | Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite — the same axis semaglutide works through. |
| GIP receptor agonism | Adds glucose-dependent insulinotropic polypeptide signaling, which appears to further improve insulin sensitivity and may contribute to appetite and weight effects. |
| Once-weekly pharmacokinetics | A fatty-acid side chain drives albumin binding and a roughly 5-day half-life, supporting once-weekly subcutaneous dosing. |
| Net metabolic effect | Lower fasting and post-meal glucose, reduced caloric intake, and substantial weight loss across trial populations. |
Evidence Summary
Unlike most peptides catalogued here, tirzepatide carries a large, high-quality human evidence base — the SURPASS (diabetes) and SURMOUNT (obesity) phase 3 programs, plus regulatory review.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| Glycemic control (T2D) | Large HbA1c reductions | Human RCT (SURPASS) | Often outperformed comparators including semaglutide 1 mg and insulin. Basis for Mounjaro approval. |
| Weight loss | Up to ~20% mean reduction | Human RCT (SURMOUNT-1) | Over 72 weeks in adults without diabetes. Basis for Zepbound approval. |
| Obstructive sleep apnea | Reduced apnea-hypopnea index | Human RCT (SURMOUNT-OSA) | Added Zepbound indication (2024). |
| Cardiometabolic markers | Improved BP, lipids, waist | Human RCT | Consistent secondary endpoints across the program. |
| Cardiovascular outcomes | Long-term CV benefit still being characterized | Human RCT | Dedicated outcomes trial reported; evidence evolving. |
| Human clinical trials | Extensive phase 3 program | Human RCT | Tens of thousands of participants underpinning FDA and international approvals. Strongest evidence tier on this site. |
Divergence — What This Means
The gap here is sourcing, not dose.
Divergence is low. Because tirzepatide is an approved medicine with a published label, community and telehealth use largely tracks the same molecule, indications and titration schedule regulators reviewed.
The meaningful gap is not dose but source quality: gray-market and research-labeled “tirzepatide” vials sold outside the pharmacy channel carry identity, purity and sterility uncertainty that the brand products (Mounjaro, Zepbound) do not. When people diverge, it is usually by sourcing, not by protocol.
The meaningful gap is not dose but source quality: gray-market and research-labeled “tirzepatide” vials sold outside the pharmacy channel carry identity, purity and sterility uncertainty that the brand products (Mounjaro, Zepbound) do not. When people diverge, it is usually by sourcing, not by protocol.
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Starting dose
2.5 mg
weekly SC, 4 weeks (initiation, not therapeutic)
First step-up
5 mg
weekly after week 4; a maintenance option
Titration
+2.5 mg
increments no sooner than every 4 weeks
Maintenance / max
5 / 10 / 15 mg
weekly; maximum 15 mg per label
Figures reflect the FDA-approved label titration for Mounjaro and Zepbound and are provided as reference only — not medical advice. Dosing should be set and adjusted by a licensed prescriber based on indication, tolerability and individual factors.
Safety Profile
Tirzepatide has a characterized safety profile from its trial program and label. The most common effects are gastrointestinal and dose-related; serious risks are boxed or highlighted on the label.
Animal / preclinical — signals observed
Nausea, vomiting, diarrhea, constipation, reduced appetite (most common; often during titration)
Boxed warning: thyroid C-cell tumor risk in rodents; contraindicated with MTC or MEN 2 history
Pancreatitis reported; gallbladder disease (cholelithiasis)
Hypoglycemia, especially with insulin or sulfonylureas
Dehydration-related acute kidney injury from GI fluid loss
What is not known (human)
Identity, potency, purity and sterility of gray-market or research-labeled tirzepatide sold outside the pharmacy channel
Long-term effects of self-directed use outside clinical supervision
Consequences of non-label reconstitution or unverified concentrations in compounded/DIY preparations
Effects in populations excluded from trials
Adverse effects listed reflect the approved label and trial data. This is a reference summary, not a substitute for the full prescribing information or a clinician’s judgment.
Regulatory Status — Updated July 2026
An approved medicine, not a research-only peptide
Tirzepatide is FDA-approved: as Mounjaro for type 2 diabetes (2022) and as Zepbound for chronic weight management (2023) and obstructive sleep apnea in adults with obesity (2024). During the 2022–2024 supply shortage, compounding pharmacies could legally prepare tirzepatide under the FDA drug-shortage exemption. That window has closed: the FDA declared the shortage resolved in December 2024, and enforcement discretion for compounded tirzepatide ended in early 2025. Legally supplied tirzepatide now comes through the approved brand products. Track current status →
Where to Source
Source research-grade Tirzepatide
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source Tirzepatide.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
Yes. It is approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity. It is a fully approved prescription medicine, not a research-only compound.
Brand tirzepatide (Mounjaro, Zepbound) is FDA-approved and manufactured to regulated standards. Compounded tirzepatide was only broadly permitted while the drug was on the FDA shortage list. Since tirzepatide came off that list and enforcement discretion ended in early 2025, legal supply runs through the approved brand products. Products still sold as compounded, gray-market or “research” tirzepatide fall outside that channel and carry quality uncertainty.
No. The FDA determined the tirzepatide shortage resolved in December 2024. Because the shortage exemption that allowed widespread compounding depended on that listing, the basis for routine compounding wound down through early 2025.
Tirzepatide activates both the GIP and GLP-1 receptors, whereas semaglutide targets GLP-1 alone. In head-to-head trial data (SURPASS-2), tirzepatide produced greater glycemic and weight reductions, though individual response and tolerability vary.
Compare Tirzepatide